A clinical trial update dated October 2, 2026 reports on a study titled "Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)." The trial is registered as NCT04086485 and is listed in Phase 1/Phase 2. Its current status is recruiting, meaning the study is actively enrolling participants as of the date reported. The trial is evaluating Lu-177-DOTATATE, known by the brand name Lutathera, used in combination with olaparib in patients with inoperable gastroenteropancreatico neuroendocrine tumors. Somatostatin and its analog pathways are relevant to this therapeutic area, as Lutathera is a radiolabeled somatostatin analog therapy. No results, efficacy data, or safety findings have been posted for this trial at this stage. This update reflects only the recruitment status and trial design as registered. Readers interested in the broader context of this treatment approach should note that somatostatin remains classified as unapproved for research use in the context referenced here. For more background on somatostatin as a compound, readers can consult the compound overview for additional context.
Trial Update: Lutathera Plus Olaparib Study in GEP-NET Recruiting
See the full somatostatin overview
Source: https://clinicaltrials.gov/study/NCT04086485